[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,47,75,101,134,164,186,210,235,262,287],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100540311","stroke-alarm-efficacy-trial-100540311",false,"NCT06315192","Stroke Alarm Efficacy Trial","StrokeAlarmEFF","INCLUSION CRITERIA\n\n1. Age 50 years or older\n2. Modified Rankin scale of 0-2.\n3. Diagnosed with either:\n\n   A. Recent\\* transient ischemic attack (TIA, G45.9), AND:\n   * ABCD2 score of ≥6, OR:\n   * Atrial fibrillation OR:\n   * Large artery atherosclerosis\\*\\*.\n\n   B. Recent\\* acute ischemic stroke (I63), AND:\n\n   • Atrial fibrillation, OR:\n   * Large artery atherosclerosis\\*\\*. C. Atrial fibrillation\u002Fflutter (I48), AND\n   * None, or reduced dose of, oral anticoagulation medication\\*\\*\\*, AND\n   * CHA2DS2-VASC score ≥4.\n\n   D. Recent\\* intracerebral hemorrhage (I61.9), AND:\n\n   • Atrial fibrillation.\n4. The patient has received the required information about the study and agrees in writing to participate.\n5. Smartphone user since at least 1 year.\n\n   * Within the last 2 weeks \\*\\*Atherosclerosis in carotid, vertebral aortic arch or major intracerebral arteries according to CTA or ultrasound.\n\n     * Including all oral anticoagulation medication such as Warfarin and NOACs. Patients with reduced dose of a NOAC can be included, regardless if this is within the approved label, or if reduced dose is chosen off-label for other reasons. Treatment with antiplatelet medication is permissible.\n\nEXCLUSION CRITERIA\n\n1. Previous inclusion in this study.\n2. Arm motor deficit from any previous medical condition.\n3. Unable to give informed consent to participate in the study.\n4. Does not master any of the languages available within the Stroke Alarm smartphone app in speech and writing.\n5. Does not have access to a Stroke Alarm compatible smartphone.\n6. Deemed unable to handle the Stroke Alarm smartphone app, or participate in planned follow-up within the framework of the study due to other diseases or circumstances.\n7. Does not want to participate.","ALL","18 Years",{"count":19,"type":20},500,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of this study is to test the efficacy of the CE-marked wearable system Stroke Alarm to identify the onset of a stroke with unilateral arm motor deficit within 3 hours of onset.\n\nThis is a multicenter, prospective observational single-arm trial with a registry-based propensity matched control population.\n\nA total of 500 patients will be included in the trial. An interim analysis will determine if the stroke onset frequency is sufficient to determine the main outcome. Should the number of stroke events differ from what is expected at interim analysis, study enrollment will continue to increase cohort size.\n\nPatients who meet the criteria for participation will, after signing consent, be included and receive the Stroke Alarm bracelets that are used for 3 months. Study data will be collected as baseline at inclusion, at follow-up 3 months after inclusion and by using national Swedish registry data after completion of the study.\n\nPatients with elevated stroke risk according assessed by presence of specific criteria associated with elevated risk caused by:\n\n1. recent TIA with an ABCD2 score of ≥6, large artery atherosclerosis or atrial fibrillation, OR\n2. recent ischemic stroke with large artery atherosclerosis or atrial fibrillation, without persisting arm motor deficit, OR\n3. atrial fibrillation with an CHA2DS2-Vasc score ≥ 4 without adequate anticoagulation OR\n4. recent hemorrhagic stroke with atrial fibrillation, without persisting arm motor deficit The combined efficacy goal is at least 60% sensitivity for Stroke Alarm b of stroke with unilateral arm motor deficit within 3 hours of onset (with a 95% confidence interval above 30%) and a specificity of at least 80% using a clinical stroke diagnosis as gold standard.\n\nA control population matched for calendar year, age (± 5 years), sex, healthcare region, baseline stroke severity according to the National Institutes of Health Stroke Scale (NIHSS, ± 5 points), unilateral arm motor deficit (NIHSS item 5a\u002F5b 1-4), presence of neglect\u002Finattention (NIHSS item 11 1-2), atrial fibrillation, cohabitation status and pre-stroke functional level twill be identified in the Swedish national stroke registry, Riksstroke, and used for comparison.",[26,27,28],"Stroke Acute","Atrial Fibrillation","TIA",[30,31,32,33],"Stroke","wearable","indication","sensor","RECRUITING","2026-06-29",{"date":37,"type":38},"2026-06-30","ACTUAL",{"date":40,"type":38},"2024-09-05",{"date":42,"type":20},"2027-12-31",{"name":44,"class":45},"Region Skane","OTHER",10,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100479078","platelet-expression-of-fcriia-and-arterial-hemodynamics-to-predict-recurrent-stroke-in-intracranial-atherosclerosis-100479078","NCT05518305","Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis","Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosi","FCG","Inclusion Criteria:\n\n* Stroke is defined as symptoms lasting \\>24 hours and associated with imaging evidence of acute ischemia in the distribution of the stenotic vessel on head CT or brain MRI. Minor stroke is defined as NIHSS\\\u003C6, as used in prior studies.\n* Eligible TIA, defined as transient neurological symptoms lasting \\\u003C24 hours, need to be: a) accompanied by DWI abnormalities in the distribution of the stenotic artery; or b) multiple (\\>1), stereotyped events associated with unequivocal ischemic symptoms (i.e. weakness, aphasia, diplopia), and attributed to the symptomatic artery. The intent of these restrictive inclusion criteria for TIA is to exclude potential stroke mimics.\n* ICAD should involve the intracranial carotid, middle cerebral, intracranial vertebral or basilar arteries. Isolated anterior and posterior cerebral artery stenosis is not included as it is uncommon in these locations and non-invasive criteria for high-grade ICAD are not well established for these vessels.\n* Stenosis 50-99% will be quantified by CTA. The criteria for 50-99% are: measured stenosis by WASID criteria (percent stenosis = (1-\\[diameter stenosis\u002Fdiameter normal\\]) x 100%.\n* Age ³30; those 30-49 years of age must also have the presence of established atherosclerotic disease in another vascular bed (coronary, extracranial carotid, peripheral) or the presence of 2 or more risk factors (hypertension, diabetes mellitus, hyperlipidemia, tobacco abuse within the last 2 years). The rationale for this criterion is to exclude non-atherosclerotic vasculopathies.\n* Provide informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Other determined etiology or established cause of the acute stroke or TIA: atrial fibrillation, mitral stenosis, mechanical valve, intracardiac thrombus or vegetation, dilated cardiomyopathy or ejection fraction \\\u003C30%, proximal extracranial carotid or vertebral stenosis \\>50%.\n* Contraindications to MRI, including MR-incompatible metallic implants (i.e. certain artificial cardiac valves, penile implants, other prosthesis), implanted electronic devices (i.e. pacemaker\u002Fdefibrillator, neurostimulators, cochlear implants), other potentially mobile ferromagnetic material (i.e. shrapnel, magnetic aneurysm clips), pregnancy (women in fertile age should have a negative pregnancy test), lactation, morbid obesity, and severe claustrophobia.",true,"30 Years",{"count":58,"type":20},250,"OBSERVATIONAL","An observational study to determine if individuals with increased platelet FcyRIIa will have a higher risk of ischemic events.",[30,28,62,63],"Ischemic Stroke","Ischemic",[30],"2026-06-09",{"date":67,"type":38},"2026-06-11",{"date":69,"type":38},"2022-09-30",{"date":71,"type":20},"2027-09-30",{"name":73,"class":45},"University of California, Los Angeles",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":55,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":85,"studyType":59,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":74},"100562580","somatic-dysfunction-in-patients-with-acute-cerebrovascular-disease-100562580","NCT06605014","Somatic Dysfunction in Patients With Acute Cerebrovascular Disease","Characterization of Somatic Dysfunction in Patients With Acute Cerebrovascular Disease","SOMADC-AC","Inclusion Criteria:\n\n* adults ≥18 years\n\nAdmission diagnosis:\n\n* ischemic stroke OR\n* transient ischemic attack (TIA). A prior history of TIA but without stroke may be enrolled.\n* Neurologic stability or lack of significant deterioration (i.e. ∆ NIHSS\\\u003C4) for at least 24 hours (defined by clinical documentation and\u002For communication with provider team(s)) in stroke subjects\n* Able to sit upright, lie supine, and when able lateral recumbent left\u002Fright positions with assist independently or with minimal person assist\n* Anticipated length of stay greater \\> or = 2 days for ischemic stroke. TIA patients average length of stay is \\\u003C 2 days, and can be enrolled in the study.\n\nExclusion Criteria:\n\n* Acute skeletal fracture or known dislocation; history of pathologic (osteoporotic or neoplastic) skeletal fracture of thoracic cage, hip\u002Fpelvis\u002Fsacrum, or vertebral column\n* Prior history of ICH, ischemic stroke, confirmed by imaging and\u002For clinical evaluation. Patients with imaging showing \"chronic stroke\" who have never received a diagnosis of stroke and\u002For have not been previously symptomatic may still be enrolled, based on the Investigator's clinical judgement.\n* Spinal column support brace (e.g. cervical collar)\n* Anticipated neurosurgical intervention during hospitalization: decompressive hemicraniectomy, hematoma evacuation (defined by clinical documentation and\u002For communication with provider team(s))\n* Current endotracheal intubation (\\*note: extubated patients can be evaluated for eligibility)\n* History of spinal cord injury with residual neuromuscular or sensory disability\n* History of recent trauma within the past 30 days\n* Known ligament, musculotendinous, or bone lesion\n* Clinical condition that would interfere with execution of movement or palpatory diagnostic testing, e.g. chronic pain\n* History of spinal surgery",{"count":84,"type":20},120,"90 Days","The goals of this observational study are to test the reliability of a new, standardized physical examination method to identify motion problems within joints or groups of joints among adult asymptomatic volunteers and in patients hospitalized with stroke or stroke-like episodes (e.g., transient ischemic attack, TIA). The main questions this investigation aims to answer are:\n\n* Can different, independent providers reliability quantify motion pattern problems using a systematic approach called, The Functional Pathology of the Musculoskeletal System (FPMSS) model?\n* Are there differences in joint(s) motion patterns among asymptomatic volunteers, patients with TIA (people with brain disease without new neurologic disability), and recent ischemic stroke (patients with new stroke-related-disability, e.g., paralysis)?\n* Is there an association between joint(s) motion impairment severity and stroke survivor outcomes?\n\nParticipants (asymptomatic and those with stroke) will undergo a set of repeated paired, musculoskeletal physical exams by independent providers blinded to each other's assessments and patient information. Researchers will compare the severity, location, and quantity of joint(s) motion impairment between these three groups with the physical examination methodology (FPMSS). Clinical information (e.g., test results, diagnoses, brain imaging, medical history) will be collected from patients admitted for TIA and stroke. Enrolled participants with recent stroke will complete a survey three months after hospitalization to determine their self-perceived quality-of-life.",[88,28,89,90,91],"Stroke, Acute","Reproducibility of Results","Osteopathic Manipulation","Health-Related Quality-of-Life","2025-09-24",{"date":94,"type":38},"2025-09-26",{"date":96,"type":38},"2023-09-01",{"date":98,"type":20},"2026-08-31",{"name":100,"class":45},"University of California, Davis",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":111,"briefSummary":113,"conditions":114,"keywords":121,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":74},"100475904","phase-3-evaluation-of-low-dose-colchicine-and-ticagrelor-in-prevention-of-ischemic-stroke-in-patients-with-stroke-due-to-atherosclerosis-100475904","NCT05476991","Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis","Reducing Inflammation in Ischemic Stroke With Colchicine, and Ticagrelor in High-risk Patients-extended Treatment in Ischemic Stroke","RIISC-THETIS","Inclusion criteria:\n\nPatient should have the following:\n\nPatient with:\n\n1. Cerebral infarction (CI) proven by neuro-imaging (MRI or head-CT), immediately once the neurologic deficit is stabilized (investigator judgement) if the patient was on antiplatelet agent monotherapy after the qualifying event, or after 21 days if the patient was on clopidogrel plus aspirin after the qualifying event, or after 21 to 30 days if the patient was on ticagrelor plus aspirin after the qualifying event (TIA with documented ischemic lesion (MRI or CT) in the appropriate area corresponding to the symptoms will be considered CI, following the current definition)\n2. Or TIA lasting more 10 minutes or more (with motor symptoms or aphasia\u002Fdysarthria or visual defect), with total resolution and no brain lesion on neuro-imaging (TIA) and with ipsilateral carotid stenosis that was revascularized (endarterectomy or stenting) or with ipsilateral, potentially causal intracranial stenosis ≥70%) if the patient was on antiplatelet agent monotherapy after the qualifying event, or after 21 days if the patient was on clopidogrel plus aspirin after the qualifying event, or after 21 to 30 days if the patient was on ticagrelor plus aspirin after the qualifying event\n3. and documented atherosclerotic stenosis:\n\n   1. presence of carotid atherosclerotic stenosis (on the basis of carotid duplex, CTA, MRA, XRA - only the report will be required to document atherosclerotic disease) ipsilateral to the cerebral ischemic symptoms (stenosis defined by luminal narrowing ≥30%, judgement of the investigator)\n   2. or presence of atherosclerotic stenosis of another cerebral artery (documented vertebral artery stenosis, basilar artery stenosis, other intracranial artery stenosis) ipsilateral to the ischemic area (stenosis defined by luminal narrowing ≥30%, judgement of the investigator)\n   3. or presence of atherosclerotic disease of the aortic arch with a plaque ≥4mm in thickness with or without superimposed thrombus, or a plaque \\\u003C4 mm with a superimposed mobile thrombus (detected by transesophageal echocardiography or CT angiography)\n4. with no clear indication of colchicine treatment (gout, Mediterranean fever) and with an indication to long-term antiplatelet therapy (no clear indication to oral anticoagulant)\n5. age equal or above 18\n6. Rankin score less than ≤4 (ranges from 0 to 6, with 0 indicating no symptoms, 1 no disability, 2 to 3 needing some help with daily activities, 4 to 5 dependent or bedridden, and 6 death),\n7. fully informed and signed inform consent\n8. with social security number.\n9. medical examination before the participation to the research\n10. Under contraception in case of childbearing potential (highly effective: 1) combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation et 2) progestogen-only).\n11. Pregnancy test for women of childbearing potential\n\nExclusion Criteria:\n\n1. Colchicine treatment needed (e.g., gout, Mediterranean fever)\n2. Hypersensitivity to ticagrelor or any of the excipients.\n3. Hypersensitivity to colchicine or any of the excipients.\n4. Major digestive disorders (chronic diarrhea, inflammatory disease of the digestive tract as uncontrolled ulcerative colitis or active Crohn disease)\n5. Immunosuppression, medullary aplasia\n6. Active chronic inflammatory disease, chronic active infection, evolving cancer\n7. Hemodynamic instability (need for amines for more than 24 hours, circulatory assistance)\n8. A recent severe sepsis (7 days) or all recent acute reaches\n9. Chronic treatment (for more than 6 months) with corticosteroids or NSAIDs (or repeated high-dose intake for less than 7 days).\n10. Anticipated concomitant oral or intravenous therapy with strong CYP3A4 inhibitors or CYP3A4 substrates than cannot be stopped for the course of the course of this study\n11. CI\u002FTIA due to arterial dissection (as documented following the judgment of the investigator) or due to cardiac source of embolism without documented atherosclerotic disease (e.g., mitral stenosis or endomyocardial fibrosis, endocarditis) a patient with atrial fibrillation, or with a history of myocardial infarction, or with calcified aortic stenosis will be eligible if the above inclusion criteria are also met\\]\n12. Indication to long-term oral anticoagulant treatment (e.g., atrial fibrillation)\n13. Symptomatic hemorrhagic stroke (the mere presence of asymptomatic cerebral hemosiderin deposits -so called \"microbleedings\" - on gradient echo imaging is not an exclusion criteria)\n14. Active pathological bleeding\n15. Uncontrolled hypertension (investigator judgement)\n16. Follow-up visit impossible or anticipated bad compliance.\n17. Intercurrent disease that may interfere with evaluation of the primary end-point or that may prevent follow-up study visits..\n18. Anticipated pregnancy at time of enrollment in the study\n19. Breastfeeding woman\n20. Patients participating in another pharmaco therapeutic program with an experimental therapy that is known to affect the ticagrerlor, colchicine or aspirine therapy.\n21. Leukopenia \\\u003C3000\u002Fμl\n22. Patients with severe renal impairment (creatinine clearance \\\u003C 30 ml\u002Fmin)\n23. Patients with severe hepatic impairment\n24. Prohibited treatments: All treatments contraindicated during the use of colchicine and\u002For ticagrelor",{"count":110,"type":20},2800,[112],"PHASE3","REDUCING INFLAMMATION IN ISCHEMIC STROKE WITH COLCHICINE, AND TICAGRELOR IN HIGH-RISK PATIENTS-EXTENDED TREATMENT IN ISCHEMIC STROKE.",[30,115,116,117,118,28,119,120],"Stroke, Ischemic","Atherosclerosis","Myocardial Infarction","Coronary Syndrome","Cardiac Disease","Cerebral Infarction",[30,122,116,123,124],"Colchicine","Aspirin","Ticagrelor","2025-09-01",{"date":127,"type":38},"2025-09-08",{"date":129,"type":38},"2023-05-17",{"date":131,"type":20},"2027-09-01",{"name":133,"class":45},"Assistance Publique - Hôpitaux de Paris",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":142,"conditions":143,"keywords":148,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":74},"100591940","beacon-tip-sizing-catheter-and-slip-cath-beacon-tip-catheter-study-100591940","NCT06986954","Beacon Tip Sizing Catheter and Slip-Cath Beacon Tip Catheter Study","Inclusion Criteria:\n\n* A patient is deemed suitable for inclusion in this study if the patient undergoes a procedure using an applicable Beacon Tip Catheter.\n\nExclusion Criteria:\n\n* Patient or his\u002Fher legally authorized representative objects to collection and processing of his\u002Fher data, or not willing to accept the use of an Informed Consent waiver or the data protection notice (if utilized).",{"count":141,"type":20},588,"This prospective observational post-market clinical study will collect data in the United States to primarily support the re-launch of the re-designed Beacon Tip Sizing Catheter and Slip-Catheter Beacon Tip Catheter \\& Shuttle Select Slip-Catheter (Visceral and Cerbral) for a Conformité Européenne (CE) Mark application in the European Union (EU). Additionally, the data from this study may be used to support regulatory approval in other countries\u002Fregions.\n\nThe purpose of this clinical study is to evaluate the safety and performance of these catheters in accordance with the Intended Use through the end of index procedure, and through 30 days post procedure, (as applicable as data is available) to ensure an acceptable benefit:risk ratio.",[144,145,30,28,146,147],"Stenosis","Bleed Intracranial","Vascular Malformation","Pseudoaneurysm",[149,150,151,152,153],"Catheter","Beacon","Diagnostic imaging","Device sizing","Beacon tip slip cath","2025-07-15",{"date":156,"type":38},"2025-07-16",{"date":158,"type":38},"2025-04-20",{"date":160,"type":20},"2026-07-31",{"name":162,"class":163},"Cook Research Incorporated","INDUSTRY",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":74},"100468339","the-akershus-study-of-ischemic-stroke-and-thrombolysis--1-100468339","NCT05378490","The Akershus Study of Ischemic Stroke and Thrombolysis -1","The Akershus Study of Ischemic Stroke and Thrombolysis -1 (ASIST-1) Epidemiology, Clinical and Radiological Presentation and Treatment of Cerebrovascular Disease and Stroke Mimics in a Norwegian Population","ASIST-1","Inclusion Criteria:\n\n* Cerebrovascular diseases (acute ischemic stroke, intracerebral hemorrhage, transient ischemic attack) or stroke mimics\n\nExclusion Criteria:\n\n* None",{"count":173,"type":20},6000,"This observational study comprises consecutively patients with cerebrovascular diseases admitted to the Stroke Unit at Akershus University Hospital in Norway. Akershus University Hospital is the largest emergency care hospital in Norway and has a catchment area covering a population of 550.000, which is approximately 10 % of the Norwegian population and reasonably representative according to data from Statistics Norway. The hospital is public and serving both as a primary hospital and a university hospital. Due to the Norwegian, national, all-covering health-insurance, all patients enter the hospital and are considered for further in-patient care on the same conditions. The hospital has a stroke unit classified as a comprehensive stroke center according to European Stroke Organisation standards. Acute stroke management follows national and international guidelines. Overall, the ASIST-1 study will investigate management, outcome and prognosis of stroke and stroke care pathways and later follow up in primary care using several approaches combining existing clinical data from a representative population with different Norwegian health registries. Parts of the study are retrospective with prospective follow-up by health registries and parts of the study are prospective.",[88,176,115,28],"Intracerebral Hemorrhage","2025-02-03",{"date":179,"type":38},"2025-02-05",{"date":181,"type":38},"2012-01-01",{"date":183,"type":20},"2040-12-31",{"name":185,"class":45},"University Hospital, Akershus",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":194,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":209},"100576472","statins-in-frail-older-patients-with-ischemic-stroke-or-transient-ischemic-attack---the-prospective-cohort-study-100576472","NCT06785740","Statins in Frail Older Patients with Ischemic Stroke or Transient Ischemic Attack - the Prospective Cohort Study","StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Prospective Cohort Study","SAFEST-coh","Inclusion Criteria:\n\n* age = 70 years or older at the time of ischemic stroke or TIA;\n* inclusion within 6 weeks after diagnosis of ischemic stroke or TIA;\n* already using statin therapy at the time of the index event;\n* frailty as defined by a pre-event score of 4-7 and\u002For post-event score of 6-7 on the validated Clinical Frailty Scale.\n\nExclusion Criteria:\n\n* Previous serious adverse drug reactions (defined as an adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisa-tion, results in persistent or significant disability or incapacity, or is a birth defect32) to statins or other contraindications to statin use.\n* Very severe frailty or very limited life expectancy (\\\u003C 6 months) as defined by a score \\>= 8 points on the validated Clinical Frailty Scale.\n* Inability to communicate in Dutch.\n* Inability to respond to questions, either independently or with the assistance of a proxy.\n* Inability or unwillingness to provide written informed consent, either independently or with the assistance of a proxy.","70 Years","120 Years",{"count":197,"type":20},300,"Two Dutch guidelines (Stroke and Cardiovascular Risk Management) provide conflicting advice on optimal statin treatment in older patients. In the SAFEST-cohort, the investigators will assess the impact of continuing versus discontinuing a statin in frail individuals aged 70 and above with a recent ischemic stroke or transient ischemic attack (TIA) on their health-related quality of life and MACE free survival during a two-year follow-up period.",[62,28],"2025-01-19",{"date":202,"type":38},"2025-01-21",{"date":204,"type":38},"2024-11-01",{"date":206,"type":20},"2029-09",{"name":208,"class":45},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",4,{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":16,"minAge":194,"maxAge":195,"enrollmentInfo":218,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":220,"conditions":221,"keywords":222,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":234},"100554129","determining-the-mcid-for-the-topics-sf-and-promis-10-in-older-patients-that-suffered-an-ischemic-stroke-or-tia-100554129","NCT06495073","Determining the MCID for the TOPICS-SF and PROMIS-10 in Older Patients That Suffered an Ischemic Stroke or TIA","Determining the Minimal Clinically Important Difference (MCID) for the TOPICS-SF and PROMIS-10 in Older Patients That Suffered an Ischemic Stroke or Transient Ischemic Attack (TIA), Using an Anchor-based Approach","CONSIDER","Inclusion Criteria:\n\n* age = 70 years or older at the time of ischemic stroke or TIA;\n* inclusion within a week after diagnosis of ischemic stroke or TIA\n\nExclusion Criteria:\n\n* not speaking Dutch;\n* being unable to answer questions;\n* being unable or not willing to give written informed consent.",{"count":219,"type":20},125,"Patient-related outcome measures (PROMs) play a crucial role in assessing patient outcomes in healthcare. Two of these PROMs are the The Older Persons and Informal Caregivers Survey Short Form (TOPICS-SF) and Patient-Reported Outcomes Measurement Information System Global Health Short Form (PROMIS-10). The investigators aim to determine the Minimal Clinically Important Difference (MCID) for the TOPICS-SF and PROMIS-10 in older people that suffered an ischemic stroke or Transient Ischemic Attack (TIA), using an anchor-based method.",[62,28],[223,224,225],"MCID","PROMIS-10","TOPICS-SF","2024-12-02",{"date":228,"type":38},"2024-12-04",{"date":230,"type":38},"2024-05-20",{"date":232,"type":20},"2024-12-31",{"name":208,"class":45},2,{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":16,"minAge":194,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":21,"phases":245,"briefSummary":246,"conditions":247,"keywords":248,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":74},"100449589","atrial-fibrillation-screening-post-ischemic-cerebrovascular-events-100449589","NCT05134454","Atrial Fibrillation Screening Post Ischemic Cerebrovascular Events","A Multicenter, National, Investigator-initiated, Randomized, Parallel-group, Registerbased Superiority Study to Compare Extended ECG Monitoring Versus Standard ECG Monitoring of 1-2 Days in Elderly Patients With Ischemic Stroke or TIA.","AF-SPICE","Inclusion Criteria:\n\n* Patients aged ≥ 70 years\n* A diagnosis of ischemic stroke or TIA within 14 days from inclusion.\n\nExclusion Criteria:\n\n* Previously diagnosed atrial fibrillation\n* Contraindication to oral anticoagulant treatment according to Summary of Product Characteristics.\n* Indication for anticoagulant treatment other than atrial fibrillation, e.g. venous thromboembolism or mechanical heart valve prosthesis\n* Dual antiplatelet therapy not interchangeable to oral anticoagulation\n* Patients with pacemaker, implantable cardioverter defibrillator or implantable cardiac monitor.\n* Patients who, according to the investigator, will not be able to comply with the study protocol.",{"count":244,"type":20},3300,[23],"Stroke is one of the leading causes behind death and permanent disability in adults. Atrial fibrillation (AF) is the most common clinical arrhythmia and its prevalence is steeply increasing with age. Atrial fibrillation is associated with a manifold increase in the risk for stroke.\n\nIt is considered important to investigate the heart rhythm in stroke survivors without previously known AF, because detection of AF will prompt a change in antithrombotic treatment with subsequent lowering of the risk of recurrent stroke.\n\nThere are so far very few studies on the prognostic impact of ECG investigations post stroke. Despite this knowledge gap, ECG investigation post stroke is given high priority in national and international guidelines.\n\nConsiderable clinical resources are currently invested in these ECG investigations without knowledge of its utility.\n\nThe investigators plan a nationwide, randomised, register-based study (RRCT) including patients aged at least 70 years receiving in-hospital care for stroke or TIA (Transient Ischemic Attack). Included patients will be randomised to standard investigation (1-2 days of ECG ) or extended ECG investigation (14 days of ECG performed at least twice). Patients diagnosed AF will be offered anticoagulation treatment. Long-term follow-up will be performed via swedish health care registers.\n\nThe result of this trial will have major impact on the ECG screening recommendations for patients who have had stroke, a large group of patients with dismal prognosis.",[62,28],[249,28,250,251,252],"stroke","atrial fibrillation","ECG","oral anticoagulation","2024-10-08",{"date":255,"type":38},"2024-10-10",{"date":257,"type":38},"2022-01-20",{"date":259,"type":20},"2027-12",{"name":261,"class":45},"Karolinska Institutet",{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":16,"minAge":269,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":21,"phases":272,"briefSummary":273,"conditions":274,"keywords":275,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":74},"100533433","phase-3-probucol-for-symptomatic-intracranial-and-extracranial-artery-stenosis-100533433","NCT06225752","Probucol for Symptomatic Intracranial and Extracranial Artery Stenosis","A Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial of Probucol in Reducing the Risk of Recurrent Stroke in Patients With Symptomatic Intracranial and Extracranial Large-artery Stenosis","Inclusion Criteria:\n\n1.40 years or older than 40 years; 2.Ischemic stroke or transient ischemic attack (TIA); 3.Within 7 days from onset to randomization; 4.Main intracranial or extracranial arteries supplying the ischemic event region are narrowed by more than 50%; 5.Informed consent signed.\n\nExclusion Criteria:\n\n1. Presumed cardiac source of embolus, such as atrial fibrillation, prosthetic cardiac valve, endocarditis or patent foramen ovale;\n2. Stroke\u002FTIA due to arterial dissection, angioplasty, or vascular surgery;\n3. Usage of probucol within 30 days before randomization;\n4. Known allergy or sensitivity or intolerance to probucol;\n5. Myocardial disease within the past 30 days, including myocardial infarction, myocarditis;\n6. With ventricular tachycardia, bradycardia, tip-twist ventricular tachycardia；\n7. With Q-Tc interval prolongation, or currently using drugs that may cause Q-Tc interval prolongation (male Q-Tc\\>450ms, female Q-Tc\\>470ms);\n8. Cardiac syncope or unexplained syncope;\n9. Impaired hepatic (ALT or AST \\> twice the upper limit of normal range) or kidney (creatinine exceeding 1.5 times of the upper limit of normal range or eGFR less than 50 ml\u002Fmin) function at randomization;\n10. Anemia (haemoglobin \\\u003C10g\u002FdL), thrombocytopenia (platelet count \\\u003C100×109\u002FL) or leucopenia (white blood cell \\\u003C3×109\u002FL) at randomization;\n11. Planned surgery or interventional treatment requiring cessation of the study drug during the study;\n12. Participating in another clinical trial with an investigational drug or device concurrently or during the last 30 days;\n13. Pregnant or lactating women; Pregnant, currently trying to become pregnant, or of child-bearing potential and not using birth control;\n14. Severe non-cardiovascular comorbidity with a life expectancy of less than 1 years;\n15. Serious drug or alcohol abuse in the past 1 year；\n16. Inability to understand and\u002For follow research procedures due to mental, cognitive, or emotional disorders, or to be an unsuitable candidate for the study for any other considered by the investigator.","40 Years",{"count":271,"type":20},5452,[112],"This study is a multicenter, double-blind, placebo-controlled, randomized clinical trial that aims to evaluate the efficacy of probucol on the reduction of the risk of recurrent stroke in patients with symptomatic intracranial or extracranial arterial stenosis.",[62,28],[276,277],"Probucol","Recurrent stroke","2024-07-12",{"date":280,"type":38},"2024-07-15",{"date":282,"type":38},"2024-06-15",{"date":284,"type":20},"2026-10-31",{"name":286,"class":45},"First Affiliated Hospital of Wannan Medical College",{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":16,"minAge":269,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":21,"phases":296,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":303,"completionDateStruct":304,"leadSponsor":306,"locationsCount":308},"100540669","phase-3-tirofiban-for-patients-with-intracranial-artery-stenosis-and-high-risk-acute-non-disabling-cerebrovascular-eventschance-4-100540669","NCT06319846","Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4）","A Multicenter, Double-blind, Double-dummy, Randomized Clinical Trial Comparing the Efficacy and Safety of Tirofiban Versus Placebo in Preventing Recurrence of Stroke for Patients With Intracranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4）","Inclusion Criteria\n\n1. 40 years or older than 40 years;\n2. Acute cerebral ischemic event due to:\n\n   * Acute non-disabling ischemic stroke (NIHSS≤5 at the time of randomization) or,\n   * TIA with moderate-to-high risk of stroke (ABCD2 score ≥ 6 at the time of randomization);\n3. Accompanied with symptomatic intracranial artery stenosis, defined as ≥ 50% stenosis of the infarcted ipsilateral intracranial artery. Intracranial arteries include intracranial segments of internal carotid arteries, intracranial segments of vertebral arteries, M1-M2 segments of middle cerebral arteries, A1-A2 segments of anterior cerebral arteries, P1-P2 segments of posterior cerebral arteries, and basilar artery. The techniques for detecting intracranial artery stenosis are limited to: MRA, CTA, or DSA. The measurement for the degree of stenosis has been established by the WASID (Warfarin-Aspirin Symptomatic Intracranial Disease) study. (AJNR Am J Neuroradiol. 2000;21:643-646.);\n4. Can be treated with study drug within 24 hours of symptoms onset\\*(\\*Symptom onset is defined by the \"last seen normal\" principle);\n5. Informed consent signed.\n\nExclusion Criteria\n\n1. Malformation, tumor, abscess or other major non-ischemic brain disease (e.g., multiple sclerosis) on baseline head CT or MRI.\n2. Unable to complete the evaluation of intracranial artery stenosis before randomization.\n3. Isolated or pure sensory symptoms (e.g., numbness), isolated visual changes, or isolated dizziness\u002Fvertigo without evidence of acute infarction on baseline head CT or MRI.\n4. Iatrogenic causes (angioplasty or surgery) of minor stroke or TIA.\n5. A score of \\> 2 on the modified Rankin scale before the symptom onset.\n6. Contraindication for tirofiban:\n\n   * Known allergy\n   * Severe renal (creatinine exceeding 1.5 times of the upper limit of normal range) or hepatic (ALT or AST \\> twice the upper limit of normal range) insufficiency\n   * Severe cardiac failure (NYHA level: III to IV)\n   * History of hemostatic disorder or systemic bleeding\n   * History of thrombocytopenia or neutropenia\n   * History of drug-induced hematologic disorder or hepatic dysfunction\n   * Low white blood cell (\\\u003C2×109\u002FL) or platelet count (\\\u003C100×109\u002FL)\n7. Tirofiban has been used since this onset.\n8. Hematocrit (HCT) \\\u003C30%.\n9. Clear indication for anticoagulation (presumed cardiac source of embolus, e.g., atrial fibrillation, prosthetic cardiac valves known or suspected endocarditis).\n10. History of intracranial hemorrhage or amyloid angiopathy.\n11. History of aneurysm (including intracranial aneurysm and peripheral aneurysm).\n12. History of asthma or COPD (chronic obstructive pulmonary disease).\n13. High-risk for bradyarrhythmia (sinus node disease, first-degree or second-degree AV block, and brady-arrhythmic syncope without pacemaker).\n14. Planned or likely revascularization (any angioplasty or endovascular surgery) within the next 3 months.\n15. Scheduled for surgery or interventional treatment requiring study drug cessation.\n16. Severe non-cardiovascular comorbidity with life expectancy \\\u003C 3 months.\n17. Inability to understand and\u002For follow research procedures due to mental, cognitive, or emotional disorders.\n18. Current treatment (last dose given within 10 days before randomization) with heparin therapy or oral anti coagulation.\n19. Intravenous thrombolytic therapy (such as intravenous rtPA) or mechanical thrombectomy within 24 hours prior to randomization.\n20. Participants who have large areas (greater than half of middle cerebral artery territory) of obvious low density on the baseline CT scan.\n21. Gastrointestinal bleed within 3 months or major surgery within 30 days.\n22. Diagnosis or suspicious diagnosis of acute coronary syndrome.\n23. Participation in another clinical study with an experimental product during the last 30 days.\n24. Currently receiving an experimental drug or device.\n25. Pregnant, currently trying to become pregnant, or of child-bearing potential and not using birth control.",{"count":295,"type":20},4674,[112],"This is a multicenter, double-blind, double-dummy, randomized clinical trial comparing the efficacy and safety of tirofiban versus placebo in preventing recurrence of stroke for patients with intracranial artery stenosis and high-risk acute non-disabling cerebrovascular events.",[299,28,300],"Ischemic Stroke, Acute","Symptomatic Intracranial Artery Stenosis","2024-07-11",{"date":278,"type":38},{"date":301,"type":38},{"date":305,"type":20},"2026-12",{"name":307,"class":45},"Beijing Tiantan Hospital",5]